Our aim is to provide novel antibacterials for human and animal infections therapy. Cell division and cell wall biosynthetic proteins, used as targets, will configure assays for screening natural product, synthetic compound, and "biased" chemical libraries to select candidate molecules for development as novel antibiotics. We will investigate the biochemical activities of, and obtain protein structures for, the targeted proteins to provide structure-activity relationship data for the chemical optimisation of lead compounds. The project integrates the production of new knowledge, from the application of innovative technologies (genomics, bioinformatics, structural biology, screening technologies), to provide improved healthcare products. Participation of two leading pharmaceutical companies guarantees a link between the generation of new knowledge and the ability to exploit the results for the benefit of the end consumer.
Funding SchemeCSC - Cost-sharing contracts